Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $10.7 million.

  • SAB Biotherapeutics' Shares Outstanding (Weighted Average) rose 1513.42% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year increase of 1513.42%. This contributed to the annual value of $9.3 million for FY2024, which is 6774.32% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Shares Outstanding (Weighted Average) stood at $10.7 million, which was up 1513.42% from $9.3 million recorded in Q2 2025.
  • SAB Biotherapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $43.0 million during Q2 2022, with a 5-year trough of $4.4 million in Q4 2022.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $15.0 million, with a median of $9.3 million in 2024.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 99356.72% in 2021, then tumbled by 8828.73% in 2023.
  • SAB Biotherapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $27.3 million in 2021, then plummeted by 84.08% to $4.4 million in 2022, then increased by 26.86% to $5.5 million in 2023, then surged by 67.74% to $9.3 million in 2024, then grew by 15.1% to $10.7 million in 2025.
  • Its last three reported values are $10.7 million in Q3 2025, $9.3 million for Q2 2025, and $9.3 million during Q1 2025.